Proposals to curb high drug prices are hardly evidence-based26-03-2020
Solutions proposed to curb the sky-high prices of new anti-cancer drugs, and thus ensure access to them, are insufficiently empirically and quantitatively substantiated, according to a study by researchers from the Netherlands Cancer Institute. The results of their study were published in the scientific journal JAMA on 26 March 2020. The researchers are currently investigating several promising policy proposals using game theory and computer simulations.
Health care system under pressure
More and more new anti-cancer drugs are being brought to market, but the prices of these drugs, such as immune therapies or targeted drugs, are often excessively high, even when they are first introduced. As a result of this, our health care system is under serious pressure, potentially limiting access to these drugs for people who need them. For this reason, the scientific literature proposes various solutions to curb sky-high drug prices. But how evidence-based are these solutions?